Last updated: July 29, 2026
Executive summary
- Glutethimide is a legacy central nervous system depressant historically used for insomnia. In the US, its availability is limited and commercialization is not consistent with a modern, high-volume branded product model.
- Financial trajectory is structurally constrained by (1) long elapsed patent and regulatory exclusivity timelines typical of pre-1990s small-molecule drugs, (2) high likelihood of generic market saturation, and (3) persistent controlled-substance and safety scrutiny that suppresses stable, scaled demand.
- Market dynamics are driven less by FDA-era exclusivity and more by supply continuity, regulatory/controlled-substance controls, and generic substitution economics.
- No reliable, present-tense branded revenue or “current year” financial trajectory can be stated from market-wide public datasets without specific issuer-level disclosures for a currently marketed US product, which is not provided here.
How is glutethimide marketed today in the US and what drives demand?
Answer: Glutethimide demand is constrained by its legacy status, controlled-substance controls, and safety risk profile, with market activity largely tied to generic supply availability rather than brand-led prescribing growth.
US commercial footprint: what typically matters for legacy small molecules
Key dynamics that govern sales velocity for older CNS drugs:
- Formulary access and substitution: If generics exist, clinicians and payers often default to lower-cost options.
- Safety and monitoring: CNS depressants face prescribing friction due to sedation, respiratory depression risk, and abuse potential.
- Regulatory classification and handling: Controlled-substance status affects procurement, distribution, and institutional prescribing practices.
- Supply chain continuity: For older molecules, intermittent manufacturing and limited supplier counts can create short-lived price spikes and then rapid normalization.
Demand-side drivers that are specific to insomnia and CNS depressants
- Insomnia prescribing is increasingly served by drugs with better tolerability and guideline alignment.
- Alternatives often include non-benzodiazepine hypnotics and other sleep agents, which reduces residual demand for older sedatives.
- Patient safety scrutiny and insurer utilization management reduce steady-state demand.
What patents protect glutethimide and when do they expire (US and key jurisdictions)?
Answer: Glutethimide is a legacy molecule; patent protection and regulatory exclusivities from original development have long since elapsed in major markets, which structurally favors generic availability.
Patent estate reality check for pre-1990 molecules
For drugs first developed in earlier decades, the practical timeline is:
- Composition-of-matter and process patents (if any survived) expire decades earlier than current markets.
- Any remaining method-of-use or formulation patents typically face narrow scope, and enforcement would be rare absent ongoing brand commercialization.
Practical implication for market economics
When patent exclusivity has already expired:
- Market is governed by generic competition and ingredient and manufacturing cost curves, not by branded R&D monetization.
- Pricing tends to compress quickly once additional suppliers launch.
What is the Orange Book status of glutethimide and are there listed patents?
Answer: The Orange Book listing pattern for legacy substances usually shows no active branded exclusivity with enforceable, currently relevant patent listings, and if any exist they are typically tied to older approvals and have aged out.
What you would expect to see if a modern branded listing existed
- A current NDA holder with “active” patent links and a continuing exclusivity clock.
- Ongoing branded marketing that justifies litigation and Paragraph IV campaigns.
For glutethimide, market behavior is more consistent with a product that is not anchored by ongoing branded exclusivity.
Which generic companies sell glutethimide and how does generic competition affect price?
Answer: Glutethimide’s competitive landscape is typically characterized by a small number of generic manufacturers supplying a thin demand base, where pricing reacts to supply availability and manufacturing margins.
Generic competition mechanics for legacy CNS drugs
- Entry and supply: If ingredient and regulatory hurdles are manageable, additional generics can enter, pushing prices down.
- Thin demand: Lower absolute volume reduces long-term margin attractiveness and can limit the number of sustained suppliers.
- Price volatility: Supplier attrition or episodic shortages can lift prices temporarily.
What this means for financial trajectory
- Sales do not behave like a sustained brand ramp.
- Revenue growth, when it occurs, usually comes from supply recovery rather than market expansion.
How do controlled-substance rules and safety scrutiny influence glutethimide’s market share?
Answer: Controlled-substance and safety scrutiny limit prescribing expansion and discourage growth in mainstream insomnia treatment channels.
Institutional and prescriber friction
- Higher barriers for initiation relative to non-controlled alternatives.
- Increased monitoring obligations and risk management requirements.
- Restrictive payer policies and clinician preference shifts away from older sedatives.
Resulting market outcome
- Glutethimide typically participates in a niche segment rather than a broad market category.
What FDA regulatory pathway affects glutethimide’s current commercialization?
Answer: For legacy generics, commercial pathways are generally Abbreviated New Drug Application (ANDA) based on prior approvals, with post-approval changes managed through supplement structures.
What matters for investors and licensors
- Generic approvals are usually constrained by chemistry manufacturing controls and ongoing compliance.
- For thin-demand drugs, the limiting factor is often supply capability rather than regulatory exclusivity.
How does glutethimide compare with modern insomnia drugs in market economics?
Answer: Market economics for glutethimide are structurally weaker than modern insomnia therapeutics because demand growth has migrated to newer, lower-friction options.
Competitive comparison categories
- Better safety/tolerability profile drugs tend to command higher sustained use.
- Guideline-aligned insomnia treatments reduce residual share for older CNS agents.
- Formulary preference shifts toward agents with less controlled-substance friction.
Financial implication
Even if glutethimide exists as a generic option, it is unlikely to show the kind of stable revenue trajectories seen in contemporary specialty CNS brands.
What patent litigation or Paragraph IV challenges affect glutethimide?
Answer: Paragraph IV litigation is unlikely to be a dominant driver for glutethimide’s market because enforceable patent terms tied to a modern branded product would be largely expired.
What would be required to see active Paragraph IV dynamics
- A currently marketed innovator product with live, Orange Book-listed patents.
- A generic challenger seeking entry before patent expiry.
For glutethimide, the market structure is more consistent with fully matured competition than active litigation cycles.
What settlement agreements and launch timing risks exist for glutethimide generics?
Answer: Settlement and launch-timing risk is generally low where there is no live branded patent wall, and where generic entry is governed by standard ANDA approval and supply readiness.
Residual risks that still move prices
- Manufacturer compliance failures.
- Quality issues leading to temporary withdrawal.
- Supply chain constraints affecting availability.
These risks can create short-term commercial swings even without patent barriers.
Which formulations, strengths, and routes of administration carry the most commercial relevance?
Answer: For legacy sedatives, commercial relevance concentrates on the oral solid dose and commonly dispensed strengths, with demand largely driven by existing prescribing habits and substitution patterns.
Product-level levers that affect revenue
- Strength availability and packaging size affect pharmacy ordering economics.
- Bioequivalence-driven substitution accelerates share capture.
- Market presence is sensitive to production continuity.
How strong is the patent estate for glutethimide as an asset today?
Answer: The patent estate is not likely to be a primary monetization mechanism today given the drug’s legacy timing and the absence of a modern, continuously protected brand model.
Assetization implications
- Value is more likely to be tied to manufacturing know-how, supply chain reliability, and regulatory positioning than to patent enforceability.
- Licensing or litigation is less likely to generate material returns absent a live exclusivity anchor.
Revenue exposure: what portion of the market economics is driven by glutethimide versus alternatives?
Answer: Glutethimide represents residual demand and is economically overshadowed by broader insomnia therapeutic classes served by newer agents.
Why that caps financial trajectory
- Category demand has fragmented across multiple newer options.
- Residual use does not support long-term branded-like growth even after supply stabilization.
Key takeaways
- Glutethimide’s market dynamics are dominated by legacy-drug realities: generic competition, supply continuity, and controlled-substance and safety-driven prescribing friction.
- Patent and exclusivity-driven revenue growth is not the central driver, since the molecule is long past typical exclusivity windows.
- Financial trajectory is more likely to be flat to cyclical, shaped by availability and generic market structure rather than by sustained innovation-led monetization.
- For business planning, the practical focus is regulatory manufacturing compliance and supply economics, not active patent barriers or expected exclusivity waterfalls.
FAQs
- Why does glutethimide show limited growth potential compared with modern hypnotics?
- Do controlled-substance requirements materially affect distribution and pharmacy adoption for glutethimide?
- What generic entry risks exist for legacy CNS drugs like glutethimide if there is no live Orange Book patent wall?
- How do supply disruptions change pricing and short-term sales for low-demand generic sedatives?
- What formulation changes are most commercially relevant for legacy oral sedatives when generics compete on bioequivalence?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Drug Approval Reports and Drug Trials Snapshots (for historical regulatory context). https://www.fda.gov/drugs/drug-approvals-and-databases-drug-approval-reports
